

# Kavita Y Sarin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/173723/publications.pdf>

Version: 2024-02-01

112  
papers

4,699  
citations

172207

29  
h-index

110170

64  
g-index

118  
all docs

118  
docs citations

118  
times ranked

8020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. <i>Journal of Investigative Dermatology</i> , 2022, 142, 382-389.	0.3	7
2	Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat. <i>JAMA Dermatology</i> , 2022, 158, 105.	2.0	3
3	Development of a core outcome set for basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 573-581.	0.6	5
4	Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment. <i>Science Advances</i> , 2022, 8, .	4.7	16
5	ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1. <i>Life Science Alliance</i> , 2022, 5, e202101353.	1.3	8
6	Fitzpatrick phototype disparities in identification of cutaneous malignancies by Google Reverse Image. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1415-1417.	0.6	3
7	Prevalence and risk factors for high-frequency basal cell carcinoma in the United States. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1493-1495.	0.6	2
8	A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1160-1162.	0.6	10
9	Loss-of-Function Variants in the Tumor-Suppressor Gene <i>PTPN14</i> Confer Increased Cancer Risk. <i>Cancer Research</i> , 2021, 81, 1954-1964.	0.4	15
10	Journal attitudes and outcomes of preprints in dermatology. <i>British Journal of Dermatology</i> , 2021, 185, 230-232.	1.4	1
11	Prevalence of potentially allergenic ingredients in products labeled for eczema care. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	0
12	691 Neutrophil and C5aR dynamics in hidradenitis suppurativa disease progression. <i>Journal of Investigative Dermatology</i> , 2021, 141, S120.	0.3	0
13	487 Topical MEK inhibition as precision targeted chemoprevention. <i>Journal of Investigative Dermatology</i> , 2021, 141, S84.	0.3	0
14	Automated detection of skin reactions in epicutaneous patch testing using machine learning. <i>British Journal of Dermatology</i> , 2021, 185, 456-458.	1.4	2
15	Dermatology Advances Into an Era of Precision Medicine. <i>JAMA Dermatology</i> , 2021, 157, 770-772.	2.0	1
16	Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts. <i>JAAD International</i> , 2021, 3, 42-52.	1.1	24
17	Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. <i>Cancers</i> , 2021, 13, 3870.	1.7	14
18	Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. <i>Neurology</i> , 2021, 97, S42-S49.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Retinostat Gel in Patients with Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4717-4725.	3.2	9
20	Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. <i>JCI Insight</i> , 2021, 6, .	2.3	10
21	Direct-to-consumer genetic risk scoring for melanoma improves adherence to sun-protective behaviors among increased-risk groups: Results from a prospective United States cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1035-1038.	0.6	0
22	Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 753-754.	0.6	11
23	Comparing online engagement and academic impact of dermatology research: An Altmetric Attention Score and PlumX Metrics analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 648-650.	0.6	15
24	Ways to Improve Care for LGBT Patients in Dermatology Clinics. <i>Dermatologic Clinics</i> , 2020, 38, 269-276.	1.0	5
25	AP-1 and TGF $\beta$ cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 5079.	5.8	47
26	18811 Crowdfunding for the treatment of cutaneous malignancies: Trends, correlates, and money raised. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB107.	0.6	1
27	Angular compounding for speckle reduction in optical coherence tomography using geometric image registration algorithm and digital focusing. <i>Scientific Reports</i> , 2020, 10, 1893.	1.6	8
28	Sexual and Gender Minority Curricula Within US Dermatology Residency Programs. <i>JAMA Dermatology</i> , 2020, 156, 593.	2.0	14
29	Gamification improves melanoma visual identification among high school students: Results from a randomized study. <i>Pediatric Dermatology</i> , 2020, 37, 752-753.	0.5	11
30	Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 820.	5.8	30
31	Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry. <i>JCI Insight</i> , 2020, 5, .	2.3	17
32	Patient Crowdfunding for the Treatment of Cutaneous Malignancies. <i>Dermatologic Surgery</i> , 2020, Publish Ahead of Print, 1012-1013.	0.4	1
33	Response to Shih etÂal.. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2385-2386.	0.3	0
34	Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas. <i>JAMA Dermatology</i> , 2019, 155, 1078.	2.0	21
35	Clonal replacement of tumor-specific T cells following PD-1 blockade. <i>Nature Medicine</i> , 2019, 25, 1251-1259.	15.2	974
36	Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2263-2271.e5.	0.3	24

#	ARTICLE	IF	CITATIONS
37	Assessment of readability and content of patient-initiated google search results for epidermolysis bullosa. <i>Pediatric Dermatology</i> , 2019, 36, 1004-1006.	0.5	4
38	Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment. <i>Dermatologic Surgery</i> , 2019, 45, 608-610.	0.4	2
39	Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 474-478.	1.5	1
40	Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1439-1448.	0.3	38
41	Alterations of the MEK/ERK, BMP, and Wnt/ $\beta$ 2-catenin pathways detected in the blood of individuals with lymphatic malformations. <i>PLoS ONE</i> , 2019, 14, e0213872.	1.1	10
42	533 Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>Journal of Investigative Dermatology</i> , 2019, 139, S92.	0.3	0
43	&lt;p&gt;From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)&lt;/p&gt;. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019, Volume 12, 933-942.	0.8	15
44	Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 564-566.	0.6	83
45	Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2019, 38, E57-E63.	1.6	8
46	Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection. <i>JMIR Public Health and Surveillance</i> , 2019, 5, e11264.	1.2	26
47	Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning. <i>JAMA Oncology</i> , 2018, 4, 581.	3.4	9
48	Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 36-41.e10.	0.6	22
49	Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. <i>Nature Medicine</i> , 2018, 24, 271-281.	15.2	82
50	Genomic Stability in Syndromic Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1044-1051.	0.3	20
51	Identification of Atorvastatin for Moderate to Severe Hidradenitis through Drug Repositioning Using Public Gene Expression Datasets. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1209-1212.	0.3	3
52	Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2072-2075.	0.3	20
53	Referred by Google: mining Google Trends data to identify patterns in and correlates to searches for dermatological concerns and providers. <i>British Journal of Dermatology</i> , 2018, 178, 794-795.	1.4	3
54	Azathioprine and risk of multiple keratinocyte cancers. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 27-28.e1.	0.6	17

#	ARTICLE	IF	CITATIONS
55	Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI Insight, 2018, 3, .	2.3	23
56	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of <i>BAP1</i> and Other Germline Mutations. Journal of Clinical Oncology, 2018, 36, 3485-3494.	0.8	104
57	Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014. Journal of the American Academy of Dermatology, 2018, , .	0.6	3
58	Automated Classification of Skin Lesions: From Pixels to Practice. Journal of Investigative Dermatology, 2018, 138, 2108-2110.	0.3	76
59	248 Early detection of chemotherapeutic skin toxicities in social health networks using deep learning. Journal of Investigative Dermatology, 2018, 138, S42.	0.3	0
60	TGF $\beta$ <sup>2</sup> , Fibronectin and Integrin $\alpha$ 5 $\beta$ 1 Promote Invasion in Basal Cell Carcinoma. Journal of Investigative Dermatology, 2018, 138, 2432-2442.	0.3	29
61	221 BCC to SCC pathway switching during tumor evolution and the role of the primary cilium. Journal of Investigative Dermatology, 2018, 138, S37.	0.3	0
62	164 Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. Journal of Investigative Dermatology, 2018, 138, S28.	0.3	2
63	Abstract LB-B32: Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKC $\alpha$ inhibitors. , 2018, , .		0
64	A survey of direct-to-consumer tele dermatology services available to US patients: Explosive growth, opportunities and controversy. Journal of Telemedicine and Telecare, 2017, 23, 19-25.	1.4	36
65	Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk. Journal of the American Academy of Dermatology, 2017, 76, 829-835.e1.	0.6	7
66	Association between genetic variation within vitamin D receptor $\alpha$ DNA binding sites and risk of basal cell carcinoma. International Journal of Cancer, 2017, 140, 2085-2091.	2.3	11
67	Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1107-1113.	1.1	53
68	Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. Journal of the American Academy of Dermatology, 2017, 77, 233-234.e2.	0.6	9
69	Association study of genetic variation in $\alpha$ DNA repair pathway genes and risk of basal cell carcinoma. International Journal of Cancer, 2017, 141, 952-957.	2.3	14
70	Health Cards by Google: dermatologist review of the inclusivity and utility of the medical search application. British Journal of Dermatology, 2017, 176, 1398-1400.	1.4	1
71	Basosquamous Carcinoma: Controversy, Advances, and Future Directions. Dermatologic Surgery, 2017, 43, 23-31.	0.4	32
72	Genetic diseases associated with an increased risk of skin cancer development in childhood. Current Opinion in Pediatrics, 2017, 29, 426-433.	1.0	17

#	ARTICLE	IF	CITATIONS
73	Postzygotic Mutations in Beta-Actin Are Associated with Becker's Nevus and Becker's Nevus Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1795-1798.	0.3	38
74	Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 353-354.	0.6	28
75	Genetic variants associate with systemic lupus erythematosus risk across ethnic groups. <i>British Journal of Dermatology</i> , 2017, 177, 620-621.	1.4	0
76	137 SRF/MRTF drive basal cell carcinoma growth through hedgehog pathway activation. <i>Journal of Investigative Dermatology</i> , 2017, 137, S23.	0.3	0
77	IFN $\gamma$ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , 2017, 170, 127-141.e15.	13.5	140
78	Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. <i>Pediatric Dermatology</i> , 2017, 34, e35-e36.	0.5	4
79	Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. <i>JCI Insight</i> , 2017, 2, .	2.3	49
80	Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. <i>Oncotarget</i> , 2017, 8, 17586-17592.	0.8	61
81	Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1517-1520.	0.3	14
82	Direct-to-consumer tele dermatology services for pediatric patients: Room for improvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 887-888.	0.6	14
83	Assessment of Accuracy of Patient-Initiated Differential Diagnosis Generation by Google Reverse Image Searching. <i>JAMA Dermatology</i> , 2016, 152, 1164.	2.0	7
84	Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12048.	5.8	117
85	Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12510.	5.8	94
86	Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2016, 152, 452.	2.0	82
87	Familial skin cancer syndromes. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 437-451.	0.6	46
88	Familial skin cancer syndromes. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 423-434.	0.6	54
89	An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. <i>Clinical Cancer Research</i> , 2016, 22, 1325-1329.	3.2	115
90	Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. <i>PLoS ONE</i> , 2016, 11, e0168031.	1.1	13

#	ARTICLE	IF	CITATIONS
91	The digital age of melanoma management: detection and diagnostics. <i>Melanoma Management</i> , 2015, 2, 383-391.	0.1	1
92	Core skin DC signatures control immune tolerance to skin cancer and limit anti-tumor immunity. , 2015, 3, P205.		1
93	Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3197-3200.	0.3	20
94	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 327-341.	7.7	316
95	Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 342-353.	7.7	337
96	A Subdermal Source: Contact Dermatitis. <i>American Journal of Medicine</i> , 2015, 128, 578-581.	0.6	0
97	Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2138-2141.	0.3	18
98	Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2692-2694.	0.8	12
99	Squamous Change in Basal-Cell Carcinoma with Drug Resistance. <i>New England Journal of Medicine</i> , 2015, 373, 1079-1082.	13.9	47
100	Activating HRAS Mutation in Nevus Spilus. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1766-1768.	0.3	31
101	Dermatologic applications of direct-to-consumer genomic analysis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 993-995.	0.6	2
102	Dermatomyositis associated with capecitabine in the setting of malignancy. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e47-e48.	0.6	11
103	Molecular Profiling to Diagnose a Case of Atypical Dermatomyositis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2796-2799.	0.3	6
104	Mosaic Activating RAS Mutations in Nevus Sebaceus and Nevus Sebaceus Syndrome. <i>Journal of Investigative Dermatology</i> , 2013, 133, 824-827.	0.3	55
105	Activating HRAS Mutation in Agminated Spitz Nevi Arising in a Nevus Spilus. <i>JAMA Dermatology</i> , 2013, 149, 1077.	2.0	45
106	Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. <i>Nature Medicine</i> , 2012, 18, 111-119.	15.2	103
107	Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab. <i>Archives of Dermatology</i> , 2012, 148, 990.	1.7	4
108	TERT Promotes Epithelial Proliferation through Transcriptional Control of a Myc- and Wnt-Related Developmental Program. <i>PLoS Genetics</i> , 2008, 4, e10.	1.5	283

#	ARTICLE	IF	CITATIONS
109	Aging, Graying and Loss of Melanocyte Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2007, 3, 212-217.	5.6	45
110	Conditional telomerase induction causes proliferation of hair follicle stem cells. <i>Nature</i> , 2005, 436, 1048-1052.	13.7	383
111	TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. <i>PLoS Genetics</i> , 2005, preprint, e10.	1.5	0
112	Partnering with a senior living community to optimise teledermatology via full body skin screening during the COVID-19 pandemic: A pilot programme. <i>Skin Health and Disease</i> , 0, , .	0.7	1